June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Decreased Protein Expression of P2X2 in the Retina of Type 1 Diabetic Rats Treated with Suramin and PPADS
Author Affiliations & Notes
  • Juan Gallo
    Ophthalmology, Hospital Universitario Austral, Pilar, Argentina
    Nanomedicine & Vision Group, Universidad Austral, Pilar, Argentina
  • Jorge Mancini
    Ophthalmology, Hospital Universitario Austral, Pilar, Argentina
    Nanomedicine & Vision Group, Universidad Austral, Pilar, Argentina
  • Gustavo Ortiz
    Nanomedicine & Vision Group, Universidad Austral, Pilar, Argentina
  • Juan Croxatto
    Ocular Pathology, Fundacion Oftalmologica Argentina "Jorge Malbran", Buenos Aires, Argentina
  • Footnotes
    Commercial Relationships Juan Gallo, EP2186529 B1 (P); Jorge Mancini, None; Gustavo Ortiz, None; Juan Croxatto, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 6323. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Juan Gallo, Jorge Mancini, Gustavo Ortiz, Juan Croxatto, ; Decreased Protein Expression of P2X2 in the Retina of Type 1 Diabetic Rats Treated with Suramin and PPADS. Invest. Ophthalmol. Vis. Sci. 2013;54(15):6323.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: We have previously shown that inflammatory markers and P2X2 were up-regulated in the retina of diabetic rats. The aim of this study was to evaluate the protein expression of P2X2 in the retina of diabetic animals treated by purinergic antagonists

Methods: Sixteen male Wistar rats of 250gr were treated with an intraperitoneal injection of 45mg/kg of streptozotocin. Only animals with glycemia levels above 200mg/dl were included in the study. The treated animals were divided into three groups of 4 rats. These were intraperitoneally injected with: 1) Suramin, 2) PPADS, 3) Suramin + PPADS at 9 and 26 weeks of diabetes in each group. Four remaining diabetic animals received no treatment. Twelve non-diabetic rats with the same age of diabetics were used as a control group. Animals were sacrificed after 38 weeks of diabetes. Retinas were analyzed by Western Blot using a primary antibody against P2X2.

Results: Protein expression of P2X2 was much higher in diabetics without treatment than in controls. Diabetic rats treated with Suramin, PPADS and the combined compound had a significantly lower expression of P2X2 than that found in diabetic animals without treatment.

Conclusions: P2X2 receptor seems to play a role in diabetic retinopathy development. This purinergic receptor could be a target for the treatment of this disease.

Keywords: 499 diabetic retinopathy • 688 retina • 498 diabetes  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×